https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-04 / Clin. Dev. Immunol. 2010;2010:517493
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-04 / Clin. Dev. Immunol. 2010;2010:5174932010-11-04 00:00:002019-02-15 08:52:55Dendritic cell-based immunotherapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Singapore Med J 2010 Nov;51(11):e187-90
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Singapore Med J 2010 Nov;51(11):e187-902010-11-01 00:00:002010-11-01 00:00:00Palliation of recurrent myxofibrosarcoma with radiotherapy and hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2240-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2240-22010-11-01 00:00:002019-02-15 08:52:01[WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-172010-11-01 00:00:002021-11-15 17:00:11Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Expert Rev Vaccines 2010 Nov;9(11):1275-302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Expert Rev Vaccines 2010 Nov;9(11):1275-3022010-11-01 00:00:002019-02-15 09:21:43Use of attenuated paramyxoviruses for cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Neoplasia 2010 Nov;12(11):906-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Neoplasia 2010 Nov;12(11):906-142010-11-01 00:00:002019-02-15 08:52:56RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2243-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2243-52010-11-01 00:00:002019-02-15 09:17:23[Multidisciplinary therapy for 984 cancer patients–hyperthermic immunotherapy]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Tumori 2010 Nov-Dec;96(6):902-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Tumori 2010 Nov-Dec;96(6):902-102010-11-01 00:00:002019-02-15 09:17:22The role of hyperthermia in the battle against cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Expert Opin Biol Ther 2010 Nov;10(11):1539-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Expert Opin Biol Ther 2010 Nov;10(11):1539-532010-11-01 00:00:002019-02-15 08:40:15Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
